| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/24/1996 | EP0513285B1 Imidazol-2-yl derivatives of substituted bicyclic compounds and process for their preparation |
| 01/24/1996 | EP0500686B1 Tricyclic [6,5,5]/[6,6,5]-fused oxazolidinone antibacterial agents |
| 01/24/1996 | EP0484486B1 Process for preparing a fruitjuice drink |
| 01/24/1996 | EP0319557B1 Reconstituted hdl particles and uses thereof |
| 01/24/1996 | CN1115588A Process and apparatus for etching semiconductor wafers |
| 01/24/1996 | CN1115575A Novel phenylethyl and phenylpropylamines |
| 01/24/1996 | CN1115320A Nucleosides and oligonucleotides having 2'-ether groups |
| 01/24/1996 | CN1115318A Levo- and dextro-rotary chloroscouriline (tetrahydroprotoberberines) and application thereof |
| 01/24/1996 | CN1115233A Zinc 5,5'-azo disalicylate for treatment of enteritis and ulcerous colitis |
| 01/24/1996 | CN1030768C Primidine derivatives, process for preparing same and inhibitor for androgen |
| 01/24/1996 | CN1030767C Method for preparing of 1-methylcarbapenem derivatives |
| 01/24/1996 | CN1030766C Method for preparing of serotonin 5HTIA agonists |
| 01/23/1996 | US5486636 Chemical intermediates |
| 01/23/1996 | US5486630 Legionella specific antibiotic |
| 01/23/1996 | US5486624 Free radical scavengers, tyrosinase inhibitors |
| 01/23/1996 | US5486623 Cysteine protease inhibitors containing heterocyclic leaving groups |
| 01/23/1996 | US5486612 N-benzyl dihydroindole LTD4 antagonists |
| 01/23/1996 | US5486602 Genes encoding serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors |
| 01/23/1996 | US5486541 For treating parkinson*s disease, memory disorders, alzheimer*s disease, depression or hyperactive syndrome |
| 01/23/1996 | US5486540 Cyclopentane heptanoic or heptenoic acid, 2-arylalkyl or arylalkenyl and derivatives as therapeutic agents |
| 01/23/1996 | US5486537 Cinnamic aldehyde, griseofluvin, alcohol |
| 01/23/1996 | US5486536 Sulfatides as anti-inflammatory compounds |
| 01/23/1996 | US5486535 Method for treating toxoplasmosis |
| 01/23/1996 | US5486534 3,4-substituted pyrazoles for the treatment of inflammation |
| 01/23/1996 | US5486532 Adrenergic agonist |
| 01/23/1996 | US5486531 Angina, hypotensive agents, erectile dysfunction |
| 01/23/1996 | US5486530 Use of torasemide for the treatment of brain oedemas |
| 01/23/1996 | US5486528 Antiulcer agents, anxiolytic agents |
| 01/23/1996 | US5486526 Histamine H3 -receptor antagonists and therapeutic uses thereof |
| 01/23/1996 | US5486525 Platelet activating factor antagonists: imidazopyridine indoles |
| 01/23/1996 | US5486524 Restenosis |
| 01/23/1996 | US5486523 Antiinflammatory |
| 01/23/1996 | US5486522 Carbamates of rapamycin |
| 01/23/1996 | US5486520 1,3-oxathiolanes useful in the treatment of hepatitis |
| 01/23/1996 | US5486519 Method for treatment of acute renal failure |
| 01/23/1996 | US5486518 4-indolylpiperazinyl derivatives |
| 01/23/1996 | US5486515 2-fluoroalkyl-1,4-benzoxaxines as potassium channel mediators |
| 01/23/1996 | US5486514 Carbamate derivatives |
| 01/23/1996 | US5486513 2-substituted indane-2-mercaptoacetylamide derivatives useful as inhibitors or enkephalinase and ace |
| 01/23/1996 | US5486512 Learning enhancement |
| 01/23/1996 | US5486511 Enzyme inhibitors |
| 01/23/1996 | US5486510 Method and compositions for modulating or control of immune responses in humans |
| 01/23/1996 | US5486509 Method of preventing and treating chemotherapy-induced alopecia |
| 01/23/1996 | US5486508 Cyclodextrin composition |
| 01/23/1996 | US5486506 12-hydroxyeicosatetrarnoic acid for cardiac arrythmia agents |
| 01/23/1996 | US5486466 Enzyme inhibitors |
| 01/23/1996 | US5486362 Controlled, sustained release delivery system for treating drug dependency |
| 01/23/1996 | US5486274 Poly-substituted phthalocyanines |
| 01/23/1996 | US5486204 Method of treating a non-penetrating head wound with hypothermia |
| 01/23/1996 | US5485827 Providing nitrogen oxide for breathing |
| 01/23/1996 | CA2154414A1 Combination treatment for inhibiting bone loss |
| 01/23/1996 | CA2154116A1 1-aryl-2-acetamidopentanone derivatives for use as tachykinin receptor antagonists |
| 01/23/1996 | CA1337992C Antioxidant |
| 01/23/1996 | CA1337991C Basically substituted phenylacetonitriles, their preparation and drugs containing these compounds |
| 01/23/1996 | CA1337990C Substituted azetidinones as anti-inflammatory antidegenerative agents |
| 01/23/1996 | CA1337988C Azole derivative and azole mycocide |
| 01/23/1996 | CA1337985C 4-substituted anthracyclinones and their preparation |
| 01/23/1996 | CA1337973C Extracts of ginkgo biloba and their methods of preparation |
| 01/23/1996 | CA1337972C Agent for treating hyperuricemia |
| 01/23/1996 | CA1337970C Antibacterial adhesive composition |
| 01/23/1996 | CA1337969C Stable emulsions of highly fluorinated organic compounds |
| 01/22/1996 | EP0700378A4 Compounds which release nitric oxide |
| 01/21/1996 | CA2154026A1 5-membered heteroaryl-oxazolidinones |
| 01/21/1996 | CA2154025A1 6-membered nitrogen-containing heteroaryl-oxazolidinones |
| 01/21/1996 | CA2154024A1 Benzofuranyl- and benzothienyloxazolidinones |
| 01/20/1996 | CA2154227A1 Cephalosporins with a substituted benzyloxyimino radical in position 7, process for their preparation and their application as medecines |
| 01/19/1996 | EP0702553A4 Water soluble non-immunogenic polyamide cross-linking agents |
| 01/18/1996 | WO1996001316A1 NOVEL GROWTH OR DIFFERENTIATION FACTOR OF THE TGF-β FAMILY |
| 01/18/1996 | WO1996001278A1 Process for producing desulfated polysaccharide, and desulfated heparin |
| 01/18/1996 | WO1996001273A1 Helicobacter pylori antigenic protein preparation and immunoassays |
| 01/18/1996 | WO1996001272A1 Helicobacter proteins and vaccines |
| 01/18/1996 | WO1996001261A1 Novel carbapenem derivative |
| 01/18/1996 | WO1996001260A1 Pyridonecarboxylic acid derivative, ester thereof, salt thereof, and intermediate for synthesis of these compounds |
| 01/18/1996 | WO1996001253A2 Pla2 inhibitors and their use for inhibition of intestinal cholesterol absorption |
| 01/18/1996 | WO1996001129A1 Inclusion complexes of ranitidine |
| 01/18/1996 | WO1996001128A2 Low-dose steroid tablets containing gallic acid esters as antioxidant agent, process for the manufacture of said tablets, and uses of said tablets |
| 01/18/1996 | WO1996001127A1 Camptothecin drug combinations and medicaments with reduced side effects |
| 01/18/1996 | WO1996001121A1 Cancer therapy using lymphotoxin |
| 01/18/1996 | WO1996001118A1 Biochemically balanced peritoneal dialysis solutions |
| 01/18/1996 | WO1996001117A1 Drugs containing metronidazole or a synergistic mixture of metronidazole and clindamycin |
| 01/18/1996 | WO1996001115A1 Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis |
| 01/18/1996 | WO1996001114A1 Method for treating and preventing alzheimer's disease |
| 01/18/1996 | WO1996001113A1 Method and medicine for alleviating jet lag |
| 01/18/1996 | WO1996001112A1 Carbamazepine medicament with retarded active substance release |
| 01/18/1996 | WO1996001111A1 Use of leflunomide to control and reverse chronic allograft rejection and to prevent or control xenograft rejection |
| 01/18/1996 | WO1996001110A2 Anti-hiv triple combination |
| 01/18/1996 | WO1996001109A1 Clavulanate pharmaceutical formulations |
| 01/18/1996 | WO1996001108A1 Stereochemical wortmannin derivatives |
| 01/18/1996 | WO1996001107A1 Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses |
| 01/18/1996 | WO1996001106A1 Use of pharmaceutical agents for alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses |
| 01/18/1996 | WO1996001101A1 Desquamation compositions |
| 01/18/1996 | WO1996001098A1 Hair tonic preparation |
| 01/18/1996 | WO1996001050A1 Prevention and treatment of human herpesvirus-6 infection with quaternary ammonium compounds and/or ganglionic blocking agents |
| 01/18/1996 | WO1995034302A3 Method for reducing intraocular pressure in the mammalian eye by administration of calcium chelators |
| 01/18/1996 | DE4425280A1 Verwendung von (S)-Adenosyl-L-methionin (SAMe) und dessen physiologisch verträglichen Salzen zur Behandlung von Reperfusionsschäden, die durch temporäre fokale Ischämie ausgelöst werden Use of (S) -Adenosyl-L-methionine (SAMe) and its physiologically acceptable salts for treating reperfusion damage triggered by temporary focal ischemia |
| 01/18/1996 | DE4425255A1 Formulierung zur inhalativen Applikation Formulation for inhalation |
| 01/18/1996 | DE4425146A1 Verwendung heterocyclischer Verbindungen Use of heterocyclic compounds |
| 01/18/1996 | DE4425145A1 Verwendung von Thiazol- und Thiadiazolverbindungen Thiazole and thiadiazole compounds using |
| 01/18/1996 | DE4425144A1 Triazolverbindungen und deren Verwendung Triazole compounds and the use thereof |
| 01/18/1996 | DE4425143A1 Substituierte Pyrimidinverbindungen und deren Verwendung Substituted pyrimidine compounds and their use |